medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.medsovet-6193Research ArticleЗАБОЛЕВАНИЯ КОЖИDERMAL DISEASESТопическая терапия псориаза. Разбор клинических случаевTopical psoriasis therapy. Review of clinical caseshttps://orcid.org/0000-0003-4583-0617МатушевскаяЕ. В.MatushevskayaE. V.

Матушевская Елена Владиславовна, д.м.н., профессор, профессор кафедры дерматовенерологии и косметологии

125371, Москва, Волоколамское шоссе, д. 91

Elena V. Matushevskaya, Dr. Sci. (Med.), Рrofessor of the Department of Dermatovenereology and Cosmetology

91, Volokolamskoe Shosse, Moscow, 125371

matushevskaya@mail.ruhttps://orcid.org/0000-0002-4123-4204ВладимироваЕ. В.VladimirovaE. V.

Владимирова Елена Владимировна, к.м.н., доцент, заведующая кафедрой дерматовенерологии и косметологии

125371, Москва, Волоколамское шоссе, д. 91

Elena V. Vladimirova, Cand. Sci. (Med.), Associate Professor, Head of the Dermatovenerology and Cosmetology Department

91, Volokolamskoe Shosse, Moscow, 125371

wellena@list.ruhttps://orcid.org/0000-0001-5995-6689МатушевскаяЮ. И.MatushevskayaYu. I.

Матушевская Юлия Игоревна, к.м.н., главный врач

140013, Люберцы, ул. Коммунистическая, д. 15

Yuliya I. Matushevskaya, Cand. Sci. (Med.), the Chief Doctor

15, Kommunisticheskaya St., Moscow 140013

yuliya-matushevskaya@yandex.ruhttps://orcid.org/0000-0003-4024-1135АвербухЕ. А.AverbukhE. A.

Авербух Елена Александровна, к.м.н., заведующий амбулаторно-поликлиническим отделением

140013, Люберцы, ул. Коммунистическая, д. 15

Elena A. Averbukh, Cand. Sci. (Med.), Нead of the Polyclinic Department

15, Kommunisticheskaya St., Moscow 140013

averbukh_lkvd@mail.ruhttps://orcid.org/0000-0002-7714-3902ШаталоваА. Ю.ShatalovaA. Yu.

Шаталова Анна Юрьевна, к.м.н., врач-дерматовенеролог

140013, Люберцы, ул. Коммунистическая, д. 15

Anna Yu. Shatalova, Cand. Sci. (Med.), Dermatovenerologist

15, Kommunisticheskaya St., Moscow 140013

doc.shatalova@mail.ruАкадемия постдипломного образования Федерального научно-клинического центра специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентстваРоссияAcademy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Medical Care and Medical Technologies of the Federal Medical and Biological AgencyRussian FederationЛюберецкий кожно- венерологический диспансерРоссияLuberetskiy Dermatovenerologic DispensaryRussian Federation202104062021081318Copyright © Матушевская Е.В., Владимирова Е.В., Матушевская Ю.И., Авербух Е.А., Шаталова А.Ю., 20212021Матушевская Е.В., Владимирова Е.В., Матушевская Ю.И., Авербух Е.А., Шаталова А.Ю.Matushevskaya E.V., Vladimirova E.V., Matushevskaya Y.I., Averbukh E.A., Shatalova A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6193

В статье представлены данные по изучению эффективности и безопасности препаратов группы топических кортикостероидов (ТГКС) при лечении псориаза в практике врача- дерматовенеролога. Рассмотрены вопросы этиологии и патогенеза псориаза, в развитии которого центральную роль занимает нарушение активации врожденного и адаптивного иммунитета. Выделены основные направления в лечении псориаза, основанные на международных и российских клинических рекомендациях. Определено место ТГКС в терапии псориаза. Даны рекомендации по ведению больных с псориазом и выбору метода терапии в зависимости от формы и тяжести патологического процесса с применением ТГКС в качестве первой линии терапии псориаза легкой и средней степени заболевания на основании современных отечественных и зарубежных рекомендаций. Представлены данные собственных клинических наблюдений применения микронизированного препарата Акридерм СК для лечения разных форм псориаза. Представлено подробное описание тактики ведения и результатов терапии двух пациентов с псориазом. Показана высокая эффективность топического препарата Акридерм СК в моно- и комбинированной терапии в сочетании с фототерапией у больных псориазом средней и тяжелой степени заболевания. На основании проанализированных данных зарубежных и отечественных исследований, а также собственного опыта авторов показано, что применение препарата Акридерм СК в терапии псориаза является эффективным и безопасным и соответствует требованиям современных принципов и стандартов лечения. Опыт его использования для лечения больных псориазом продемонстрировал высокую терапевтическую эффективность и низкий риск формирования нежелательных явлений.

The article presents the data concerning the efficacy and safety of topical corticosteroids (TCS) in psoriasis treatment in the practice of dermatovenerologist. The questions of etiology and pathogenesis of psoriasis are considered; violation of activation of innate and adaptive immunity plays the key role in its development. The basic approaches in psoriasis treatment, based on the international and Russian clinical guidelines, are distinguished. The place of TCS in psoriasis therapy is determined. The authors give the recommendations for the management of patients with psoriasis and the choice of therapy depending on the form and severity of the pathological process with the use of TCS as the first-line therapy of mild and moderate psoriasis on the basis of the modern Russian and foreign recommendations. The article presents the data of own clinical observations of Akriderm SK micronized drug application for treatment of different forms of psoriasis. A detailed description of management tactics and results of therapy in two patients with psoriasis is presented. The high efficacy of topical Akriderm SK drug in mono- and combined therapy in combination with phototherapy in patients with moderate to severe psoriasis has been shown. Based on the analyzed data of foreign and domestic studies, as well as the authors’ own experience, it is shown that the use of Acriderm SK in psoriasis therapy is effective and safe and meets the requirements of modern treatment principles and standards. The experience of its use for treatment of psoriasis patients demonstrated high therapeutic efficacy and low risk of adverse events.

псориазпатогенезтерапиятопические кортикостероидысалициловая кислотакомбинированная терапияpsoriasispathogenesistherapytopical corticosteroidssalicylic acidcombination therapyReferencesKurd S.K., Gelfand J.M. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60(2):218–224. doi: 10.1016/j.jaad.2008.09.022.Kurd S.K., Gelfand J.M. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60(2):218–224. doi: 10.1016/j.jaad.2008.09.022.Augustin M., Reich K., Glaeske G., Schaefer I., Radtke M. Co-morbidity and agerelated prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–151. doi: 10.2340/00015555-0770.Augustin M., Reich K., Glaeske G., Schaefer I., Radtke M. Co-morbidity and agerelated prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–151. doi: 10.2340/00015555-0770.Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320. doi: 10.1046/j.1365-2230.2001.00832.x.Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320. doi: 10.1046/j.1365-2230.2001.00832.x.Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi: 10.1038/jid.2012.339.Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi: 10.1038/jid.2012.339.Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996;35(9):633–639. doi: 10.1111/j.1365-4362.1996.tb03687.x.Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996;35(9):633–639. doi: 10.1111/j.1365-4362.1996.tb03687.x.Rachakonda T.D., Scj3.11.013.Rachakonda T.D., Scj3.11.013.Danielsen K., Olsen A.O., Wilsgaard T., Furberg A.S. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol. 2013;168(6):1303–1310. doi: 10.1111/bjd.12230.Danielsen K., Olsen A.O., Wilsgaard T., Furberg A.S. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol. 2013;168(6):1303–1310. doi: 10.1111/bjd.12230.Кубанов А.А., Бакулев А.Л., Карамова А.Э., Притуло О.А., Аршинский М.И., Знаменская Л.Ф. и др. Псориаз: клинические рекомендации. М.; 2020. 66 с. Режим доступа: https://www.rodv.ru/upload/iblock/aa2/aa20a2fc65b13df3899140167777092d.pdf.Kubanov A.A., Bakulev A.L., Karamova A.E., Pritulo O.A., Arshinskiy M.I., Znamenskaya L.F. et al. Psoriasis: clinical guidelines. Мoscow; 2020. 66 p. (In Russ.) Available at: https://www.rodv.ru/upload/iblock/aa2/aa20a2fc65b13df3899140167777092d.pdf.Trembath R.C., Clough R.L., Rosbotham J.L., Jones A.B., Camp R.D., Frodsham A. et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6(5):813–820. doi: 10.1093/hmg/6.5.813.Trembath R.C., Clough R.L., Rosbotham J.L., Jones A.B., Camp R.D., Frodsham A. et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6(5):813–820. doi: 10.1093/hmg/6.5.813.Sommer D.M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328. doi: 10.1007/s00403-006-0703-z.Sommer D.M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328. doi: 10.1007/s00403-006-0703-z.Gerdes S., Mrowietz U., Boehncke W.H. Komorbidität bei Psoriasis vulgaris. Hautarzt (German). 2016;67(6):438–444. doi: 10.1007/s00105-016-3805-3.Gerdes S., Mrowietz U., Boehncke W.H. Komorbidität bei Psoriasis vulgaris. Hautarzt (German). 2016;67(6):438–444. doi: 10.1007/s00105-016-3805-3.Rapp S.R., Feldman S.R., Exum M.L., Fleischer A.B. Jr, Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–407. doi: 10.1016/s0190-9622(99)70112-x.Rapp S.R., Feldman S.R., Exum M.L., Fleischer A.B. Jr, Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–407. doi: 10.1016/s0190-9622(99)70112-x.Di Meglio P., Villanova F., Nestle F.O. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. doi: 10.1101/cshperspect.a015354.Di Meglio P., Villanova F., Nestle F.O. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. doi: 10.1101/cshperspect.a015354.Rendon A., Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. doi: 10.3390/ijms20061475.Rendon A., Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. doi: 10.3390/ijms20061475.Harden J.L., Krueger J.G., Bowcock A.M. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66–73. doi: 10.1016/j.jaut.2015.07.008.Harden J.L., Krueger J.G., Bowcock A.M. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66–73. doi: 10.1016/j.jaut.2015.07.008.Liang Y., Sarkar M.K., Tsoi L.C., Gudjonsson J.E. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8. doi: 10.1016/j.coi.2017.07.007.Liang Y., Sarkar M.K., Tsoi L.C., Gudjonsson J.E. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8. doi: 10.1016/j.coi.2017.07.007.Morizane S., Gallo R.L. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol. 2012;39(3):225–230. doi: 10.1111/j.1346-8138.2011.01483.x.Morizane S., Gallo R.L. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol. 2012;39(3):225–230. doi: 10.1111/j.1346-8138.2011.01483.x.Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O. et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202(1):135–143. doi: 10.1084/jem.20050500.Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O. et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202(1):135–143. doi: 10.1084/jem.20050500.Gregorio J., Meller S., Conrad C., Di Nardo A., Homey B., Lauerma A. et al. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J Exp Med. 2010;207(13):2921–2930. doi: 10.1084/jem.20101102.Gregorio J., Meller S., Conrad C., Di Nardo A., Homey B., Lauerma A. et al. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J Exp Med. 2010;207(13):2921–2930. doi: 10.1084/jem.20101102.Santini S.M., Lapenta C., Donati S., Spadaro F., Belardelli F., Ferrantini M. Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. PLoS One. 2011;6(2):e17364. doi: 10.1371/journal.pone.0017364.Santini S.M., Lapenta C., Donati S., Spadaro F., Belardelli F., Ferrantini M. Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. PLoS One. 2011;6(2):e17364. doi: 10.1371/journal.pone.0017364.Hänsel A., Günther C., Ingwersen J., Starke J., Schmitz M., Bachmann M. et al. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol. 2011;127(3):787–794.e1-9. doi: 10.1016/j.jaci.2010.12.009.Hänsel A., Günther C., Ingwersen J., Starke J., Schmitz M., Bachmann M. et al. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol. 2011;127(3):787–794.e1-9. doi: 10.1016/j.jaci.2010.12.009.Morizane S., Yamasaki K., Mühleisen B., Kotol P.F., Murakami M., Aoyama Y. et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol. 2012;132(1):135–143. doi: 10.1038/jid.2011.259.Morizane S., Yamasaki K., Mühleisen B., Kotol P.F., Murakami M., Aoyama Y. et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol. 2012;132(1):135–143. doi: 10.1038/jid.2011.259.Perera G.K., Di Meglio P., Nestle F.O. Psoriasis. Annu Rev Pathol. 2012;7:385–422. doi: 10.1146/annurev-pathol-011811-132448.Perera G.K., Di Meglio P., Nestle F.O. Psoriasis. Annu Rev Pathol. 2012;7:385–422. doi: 10.1146/annurev-pathol-011811-132448.Capon F. The Genetic Basis of Psoriasis. Int J Mol Sci. 2017;18(12):2526. doi: 10.3390/ijms18122526.Capon F. The Genetic Basis of Psoriasis. Int J Mol Sci. 2017;18(12):2526. doi: 10.3390/ijms18122526.Mrowietz U., Kragballe K., Reich K., Spuls P., Griffiths C.E., Nast A. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. doi: 10.1007/s00403-010-1080-1.Mrowietz U., Kragballe K., Reich K., Spuls P., Griffiths C.E., Nast A. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. doi: 10.1007/s00403-010-1080-1.Strober B.E., van der Walt J.M., Armstrong A.W., Bourcier M., Carvalho A.V.E., Chouela E. et al. Clinical Goals and Barriers to Effective Psoriasis Care. Dermatol Ther (Heidelb). 2019;9(1):5–18. doi: 10.1007/s13555-018-0279-5.Strober B.E., van der Walt J.M., Armstrong A.W., Bourcier M., Carvalho A.V.E., Chouela E. et al. Clinical Goals and Barriers to Effective Psoriasis Care. Dermatol Ther (Heidelb). 2019;9(1):5–18. doi: 10.1007/s13555-018-0279-5.Nast A., Smith C., Spuls P.I., Avila Valle G., Bata-Csörgö Z., Boonen H. et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi: 10.1111/jdv.16915.Nast A., Smith C., Spuls P.I., Avila Valle G., Bata-Csörgö Z., Boonen H. et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi: 10.1111/jdv.16915.Ladizinski B., Lee K.C., Wilmer E., Alavi A., Mistry N., Sibbald R.G. A review of the clinical variants and the management of psoriasis. Adv Skin Wound Care. 2013;26(6):271–284. doi: 10.1097/01.ASW.0000429778.10020.67.Ladizinski B., Lee K.C., Wilmer E., Alavi A., Mistry N., Sibbald R.G. A review of the clinical variants and the management of psoriasis. Adv Skin Wound Care. 2013;26(6):271–284. doi: 10.1097/01.ASW.0000429778.10020.67.Hoegler K.M., John A.M., Handler M.Z., Schwartz R.A. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645–1651. doi: 10.1111/jdv.14949.Hoegler K.M., John A.M., Handler M.Z., Schwartz R.A. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645–1651. doi: 10.1111/jdv.14949.Zweegers J., de Jong E.M., Nijsten T.E., de Bes J., te Booij M., Borgonjen R. et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dermatol Online J. 2014;20(3). Available at: https://escholarship.org/uc/item/93n3j5s9.Zweegers J., de Jong E.M., Nijsten T.E., de Bes J., te Booij M., Borgonjen R. et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dermatol Online J. 2014;20(3). Available at: https://escholarship.org/uc/item/93n3j5s9.Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. J Cutan Med Surg. 2016;20(5):375–431. doi: 10.1177/1203475416655705.Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. J Cutan Med Surg. 2016;20(5):375–431. doi: 10.1177/1203475416655705.Merola J.F., Li T., Li W.Q., Cho E., Qureshi A.A. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486–489. doi: 10.1111/ced.12805.Merola J.F., Li T., Li W.Q., Cho E., Qureshi A.A. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486–489. doi: 10.1111/ced.12805.Merola J.F., Qureshi A., Husni M.E. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. doi: 10.1111/dth.12589.Merola J.F., Qureshi A., Husni M.E. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. doi: 10.1111/dth.12589.Jacobi A., Mayer A., Augustin M. Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review. Dermatol Ther (Heidelb). 2015;5(1):1–18. doi: 10.1007/s13555-015-0068-3.Jacobi A., Mayer A., Augustin M. Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review. Dermatol Ther (Heidelb). 2015;5(1):1–18. doi: 10.1007/s13555-015-0068-3.Chiricozzi A., Pimpinelli N., Ricceri F., Bagnoni G., Bartoli L., Bellini M. et al. Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. Dermatol Ther. 2017;30(6). doi: 10.1111/dth.12549.Chiricozzi A., Pimpinelli N., Ricceri F., Bagnoni G., Bartoli L., Bellini M. et al. Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. Dermatol Ther. 2017;30(6). doi: 10.1111/dth.12549.Nast A., Boehncke W.H., Mrowietz U., Ockenfels H.M., Philipp S., Reich K. et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304(2):87–113. doi: 10.1007/s00403-012-1214-8.Nast A., Boehncke W.H., Mrowietz U., Ockenfels H.M., Philipp S., Reich K. et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304(2):87–113. doi: 10.1007/s00403-012-1214-8.Rogers T.L., Nelsen A.C., Hu J., Brown J.N., Sarkari M., Young T.J. et al. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur J Pharm Biopharm. 2002;54(3):271–280. doi: 10.1016/s0939-6411(02)00063-2.Rogers T.L., Nelsen A.C., Hu J., Brown J.N., Sarkari M., Young T.J. et al. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur J Pharm Biopharm. 2002;54(3):271–280. doi: 10.1016/s0939-6411(02)00063-2.

The authors declare that there are no conflicts of interest present.